St. Jude is aiming to expand its portfolio of devices for the treatment of heart failure.
Bayer is shedding peripheral units as he focuses on more lucrative life-sciences operations.
The $1.2bn acquisition will boost Cardinal Health's generic drug distribution.
Opko will gain access to genetic data and sequencing technologies to aid medical discovery.
Most pharmacy benefit managers and pharmacy chain operators are consolidating.
Teva said the offer of $82 a share represented a 48% premium to Mylan's stock price on March 10.
Bristol-Myers will have exclusive access UniQure's congestive heart failure therapy.
Ardent is one of the 10 largest for-profit hospitals in the U.S. and generates about $2 billion in annual revenue.
Novartis will make an upfront payment of $200 million and Aduro could be eligible for a further $500 million.
Teva is the biggest maker of generic drugs in the world, and Auspex, does not have any products for sale yet.
Copyright © 2015. All rights reserved.